Incyte Corporation (Nasdaq: INCY) today announced its support of the first national Myelofibrosis Awareness Day, which will be held on Sept. 20, 2012. The inaugural recognition day is being led by the MPN Coalition, a group of patient advocacy organizations that have come together to help people living with myelofibrosis (MF). MF belongs to a group of diseases called myeloproliferative neoplasms (MPNs), and is a progressive, potentially life-threatening blood cancer with limited treatment options. 1 Patients with MF suffer a high disease burden characterized by bone marrow failure, enlarged spleen (splenomegaly) and debilitating symptoms including fatigue, severe itching (pruritus), night sweats, bone pain, and early satiety (a feeling of fullness), leading to impaired quality of life. 2
“Volunteers across the country are promoting Sept. 20 as Myelofibrosis Awareness Day to connect organizations, doctors and individuals affected by MF to ensure that patients and their families have the necessary information, support and resources to better manage this disease,” stated Ann Brazeau, chairperson of the MPN Coalition and Vice President of Development of the MPN Research Foundation. “The theme for the day is ‘Empower,’ and those affected by MF are being encouraged to become more knowledgeable about the disease, to be active and engaged partners in their care, and to gain strength as part of a group of individuals facing similar challenges.”
Activities and initiatives planned by the MPN Coalition, which comprises organizations including CancerCare, Cancer Support Community, MPN Research Foundation, MPN Education Foundation, The Leukemia & Lymphoma Society, and National Organization for Rare Disorders, include patient and physician educational brochures, symposia and workshops, web programs, and video interviews with key MPN researchers. Many of the activities will also include efforts to increase awareness of the symptoms that affect the daily lives of people with this disease.
“With Myelofibrosis Awareness Day, we’re encouraged to see so many important organizations come together to rally around such an important cause. Their efforts will help to bring greater understanding about this rare disease to physicians and help patients with MF become more empowered in dealing with their disease,” stated Paul A. Friedman, MD, President and Chief Executive Officer, Incyte.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV